Literature DB >> 23255085

Treatment of melasma with the 1,927-nm fractional thulium fiber laser: a retrospective analysis of 20 cases with long-term follow-up.

Ane Beatriz M Niwa Massaki1, Sasima Eimpunth, Sabrina G Fabi, Isabella Guiha, William Groff, Richard Fitzpatrick.   

Abstract

BACKGROUND: Melasma is a common acquired symmetrical hyperpigmentation that is often recurrent and refractory.
OBJECTIVES: To investigate the efficacy and safety of a single administration of high-density fractional thulium fiber laser (1,927 nm) for the treatment of refractory melasma in 20 patients.
MATERIALS AND METHODS: A retrospective chart and photographs review of 20 women (Fitzpatrick skin type II-IV) with clinical diagnosis of melasma treated with the 1,927-nm fractionated thulium laser at 10 or 20 mJ/cm(2) , with 60-70% surface area coverage. Four investigators independently evaluated Melasma Area Severity Index (MASI) scores before, 4 weeks, 3-6 months, and 6-12 months after treatment.
RESULTS: Mean MASI scores decreased dramatically from 13.2 ± 5.4 before treatment to 8.5 ± 3.5 at 4 weeks after laser treatment (P = 0.004). Patient assessment revealed that 12 of the 20 subjects had more than 50% clearance of their melasma. Recurrence was reported by 7 out of 15 patients who were successfully followed-up (mean 10.2 months). Two patients developed postinflammatory hyperpigmentation that subsided with topical bleaching after 3 months.
CONCLUSION: High-density coverage fractional 1,927-nm thulium laser proved to be safe and effective for melasma with long-term remission.
Copyright © 2012 Wiley Periodicals, Inc.

Entities:  

Mesh:

Year:  2012        PMID: 23255085     DOI: 10.1002/lsm.22100

Source DB:  PubMed          Journal:  Lasers Surg Med        ISSN: 0196-8092            Impact factor:   4.025


  9 in total

Review 1.  [Nonablative fractional lasers: Acne scars and other indications].

Authors:  K Degitz
Journal:  Hautarzt       Date:  2015-10       Impact factor: 0.751

2.  Combination of Q-Switched Nd:YAG and Fractional Erbium:YAG Lasers in Treatment of Melasma: A Randomized Controlled Clinical Trial.

Authors:  Shiva Alavi; Ehsan Abolhasani; Sharin Asadi; Mohammadali Nilforoushzadeh
Journal:  J Lasers Med Sci       Date:  2017-01-08

3.  Efficacy of 694-nm fractional Q-switched ruby laser (QSRL) combined with sonophoresis on levorotatory vitamin C for treatment of melasma in Chinese patients.

Authors:  H L Zhou; B Hu; C Zhang
Journal:  Lasers Med Sci       Date:  2016-04-28       Impact factor: 3.161

Review 4.  Confetti-like Sparing: A Diagnostic Clinical Feature of Melasma.

Authors:  Douglas C Wu; Richard E Fitzpatrick; Mitchel P Goldman
Journal:  J Clin Aesthet Dermatol       Date:  2016-02

Review 5.  A review of laser and light therapy in melasma.

Authors:  M K Trivedi; F C Yang; B K Cho
Journal:  Int J Womens Dermatol       Date:  2017-03-21

6.  Treatment of burn scars in Fitzpatrick phototype III patients with a combination of pulsed dye laser and non-ablative fractional resurfacing 1550 nm erbium:glass/1927 nm thulium laser devices.

Authors:  Joy Tao; Amanda Champlain; Charles Weddington; Lauren Moy; Rebecca Tung
Journal:  Scars Burn Heal       Date:  2018-02-23

Review 7.  Understanding Melasma-How Can Pharmacology and Cosmetology Procedures and Prevention Help to Achieve Optimal Treatment Results? A Narrative Review.

Authors:  Zuzanna Piętowska; Danuta Nowicka; Jacek C Szepietowski
Journal:  Int J Environ Res Public Health       Date:  2022-09-24       Impact factor: 4.614

Review 8.  Acquired hyperpigmentations.

Authors:  Tania Ferreira Cestari; Lia Pinheiro Dantas; Juliana Catucci Boza
Journal:  An Bras Dermatol       Date:  2014 Jan-Feb       Impact factor: 1.896

9.  1,550 nm Erbium-Doped and 1,927 nm Thulium Nonablative Fractional Laser System: Best Practices and Treatment Setting Recommendations.

Authors:  Paul M Friedman; Jeffrey S Dover; Anne Chapas; Zakia Rahman; Edward V Ross; Suzanne L Kilmer; Wendy E Roberts; Pooja Sodha; Julie B Stimmel; Mary Beth C Moncrief; Jill S Waibel
Journal:  Dermatol Surg       Date:  2022-02-01       Impact factor: 3.398

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.